

Experiment Number: 97011-17
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:46

First Dose M/F: NA / NA

Lab: MBA

C Number:	C97011B
Lock Date:	09/18/2000
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 97011-17
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/18/2014
Time Report Requested: 17:29:46
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Moribund Sacrifice		1
Natural Death		4
Survivors		
Accidentally Killed	1	
Terminal Sacrifice	14	10
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(14)
Centrilobular, Vacuolization Cytoplasmic Hepatocyte, Inflammation, Chronic Active, Focal	1 (7%)	1 (7%)
Mesentery	(1)	(0)
Fat, Necrosis, Focal	1 (100%)	
Stomach, Forestomach	(15)	(13)
Tooth	(1)	(0)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(11)
Subcapsular, Hyperplasia, Focal		1 (9%)
Zona Glomer, Hyperplasia, Focal	2 (13%)	3 (27%)
Zona Reticul, Vacuolization Cytoplasmic, Focal	3 (20%)	2 (18%)
Adrenal Medulla	(14)	(11)
Pituitary Gland	(12)	(11)
Thyroid Gland	(14)	(13)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:46

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
Ectopic Thymus		1 (8%)
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Epididymis	(15)	(13)
Hypospermia		10 (77%)
Seminal Vesicle	(0)	(3)
Atrophy, Diffuse		1 (33%)
Dilatation		2 (67%)
Testes	(15)	(12)
Germinal Epith, Degeneration	1 (7%)	11 (92%)
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(12)
Myeloid Cell, Hyperplasia		1 (8%)
Lymph Node, Mandibular	(15)	(12)
Lymph Node, Mediastinal	(11)	(10)
Lymph Node, Mesenteric	(15)	(12)
Spleen	(15)	(12)
Congestion		1 (8%)
Hematopoietic Cell Proliferation	4 (27%)	11 (92%)
Lymph Follic, Depletion Cellular, Diffuse		1 (8%)
Thymus	(15)	(10)
Atrophy, Focal		2 (20%)
INTEGUMENTARY SYSTEM		
None		
MUSCULOSKELETAL SYSTEM		
Bone	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-17
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/18/2014
Time Report Requested: 17:29:46
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	60 MG/KG
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(14)
Alveolar Epith, Hyperplasia, Focal		3 (21%)
Alveolus, Edema, Focal		1 (7%)
Alveolus, Inflammation, Chronic Active, Focal		6 (43%)
Perivascular, Infiltration Cellular, Lymphocyte		1 (7%)
SPECIAL SENSES SYSTEM		
Lacrimal Gland	(0)	(1)
URINARY SYSTEM		
Kidney	(15)	(13)
Renal Tubule, Dilatation, Focal		1 (8%)
Renal Tubule, Inflammation, Chronic Active, Focal		1 (8%)
Urinary Bladder	(15)	(12)

END OF MALE DATA

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:46

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Natural Death		1
Survivors		
Moribund Sacrifice		2
Terminal Sacrifice	15	12
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Esophagus	(0)	(1)
Periesoph Tiss, Cyst, Squamous, Focal		1 (100%)
Liver	(15)	(15)
Centrilobular, Hepatocyte, Vacuolization Cytoplasmic, Focal	2 (13%)	
Hepatocyte, Inflammation, Chronic Active, Focal	1 (7%)	
Hepatocyte, Necrosis, Focal	2 (13%)	
Hepatocyte, Vacuolization Cytoplasmic, Focal	2 (13%)	
Mesentery	(1)	(0)
Fat, Hemorrhage, Focal	1 (100%)	
Fat, Inflammation, Chronic Active, Focal	1 (100%)	
Stomach, Forestomach	(15)	(15)
Tooth	(1)	(0)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)
Subcapsular, Hyperplasia, Focal	7 (47%)	2 (13%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:46

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Zona Reticul, Vacuolization Cytoplasmic, Diffuse	1 (7%)	1 (7%)
Zona Reticul, Vacuolization Cytoplasmic, Focal	11 (73%)	9 (60%)
Adrenal Medulla	(15)	(15)
Pituitary Gland	(15)	(14)
Thyroid Gland	(14)	(14)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Ovary	(15)	(15)
Atrophy	3 (20%)	6 (40%)
Periovarn Tiss, Inflammation, Acute, Focal		1 (7%)
Periovarn Tiss, Inflammation, Chronic Active, Diffuse	1 (7%)	
Uterus	(15)	(14)
Endometrium, Hyperplasia, Cystic	12 (80%)	13 (93%)
Endometrium, Inflammation, Acute, Focal		1 (7%)
Hydrometra	2 (13%)	1 (7%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(15)	(14)
Myeloid Cell, Hyperplasia		3 (21%)
Lymph Node, Mandibular	(15)	(14)
Lymph Node, Mediastinal	(14)	(9)
Lymph Node, Mesenteric	(15)	(15)
Spleen	(15)	(14)
Hematopoietic Cell Proliferation	3 (20%)	13 (93%)
Pigmentation	5 (33%)	5 (36%)
Thymus	(15)	(14)
Atrophy, Diffuse	1 (7%)	1 (7%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-17

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/18/2014

Time Report Requested: 17:29:46

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	60 MG/KG
Atrophy, Focal	2 (13%)	1 (7%)
INTEGUMENTARY SYSTEM		
Skin	(3)	(3)
MUSCULOSKELETAL SYSTEM		
Bone	(0)	(1)
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar Epith, Hyperplasia, Focal		1 (7%)
Alveolus, Hemorrhage, Focal	1 (7%)	
Alveolus, Inflammation, Chronic Active, Focal		5 (33%)
Congestion, Diffuse		1 (7%)
Trachea	(0)	(1)
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(14)
Urinary Bladder	(14)	(14)

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion